J.P. Morgan Analyst Raises Kura Oncology Price Target to $32
J.P. Morgan analyst Priyanka Grover maintained a bullish rating on Kura Oncology and increased the price target from $30 to $32.
Stocks · News reference
Kura Oncology, Inc. announced it will release its financial results for the third quarter of 2026 after market close on Tuesday, November 10, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
J.P. Morgan analyst Priyanka Grover maintained a bullish rating on Kura Oncology and increased the price target from $30 to $32.
Kura Oncology, Inc. announced that its management team will present at the UBS Global Biopharma London Conference and the Jefferies Global Healthcare Conference in November 2026.
TD Cowen analyst Phil Nadeau has maintained a bullish rating on Kura Oncology (KURA).
Kura Oncology announced its third quarter 2026 financial results, highlighting strong commercial performance for its lead product, KOMZIFTI.
Kura Oncology, Inc. announced the grant of nonstatutory stock options to three new employees as an inducement material to their employment.
Kura Oncology and Kyowa Kirin announced that eight abstracts regarding ziftomenib have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting.